Cargando…
Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440157/ https://www.ncbi.nlm.nih.gov/pubmed/31305661 http://dx.doi.org/10.1097/MD.0000000000006958 |
| _version_ | 1783238024694333440 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5440157 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Wolters Kluwer Health |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-54401572017-05-25 Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum Medicine (Baltimore) Erratum Wolters Kluwer Health 2017-05-19 /pmc/articles/PMC5440157/ /pubmed/31305661 http://dx.doi.org/10.1097/MD.0000000000006958 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
| spellingShingle | Erratum Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum |
| title | Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum |
| title_full | Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum |
| title_fullStr | Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum |
| title_full_unstemmed | Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum |
| title_short | Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum |
| title_sort | assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: erratum |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440157/ https://www.ncbi.nlm.nih.gov/pubmed/31305661 http://dx.doi.org/10.1097/MD.0000000000006958 |